XML 43 R30.htm IDEA: XBRL DOCUMENT
v3.24.3

Equity (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2024
Stockholders' Equity Note [Abstract] |
Schedule of stock based compensation expense | Share-based compensation expense for the periods presented is as follows:
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2024 |  | 2023 |  | 2024 |  | 2023
Stock options: |  |  |  |  |  |  |  |
Pre-tax compensation expense |  | $ | 1 |  |  | $ | 1 |  |  | $ | 4 |  |  | $ | 3 |
Income tax benefit |  | — |  |  | — |  |  | — |  |  | — |
Stock option expense, net of income taxes |  | 1 |  |  | 1 |  |  | 4 |  |  | 3 |
Restricted stock units (“RSUs”): |  |  |  |  |  |  |  |
Pre-tax compensation expense |  | 4 |  |  | 4 |  |  | 15 |  |  | 11 |
Income tax benefit |  | (1) |  |  | — |  |  | (2) |  |  | (1) |
RSUs, net of income taxes |  | 3 |  |  | 4 |  |  | 13 |  |  | 10 |
Performance shares and other share-based awards: |  |  |  |  |  |  |  |
Pre-tax compensation expense |  | 3 |  |  | 4 |  |  | 11 |  |  | 9 |
Income tax benefit |  | — |  |  | (1) |  |  | — |  |  | (1) |
Performance shares and other share-based compensation expense, net of income taxes |  | 3 |  |  | 3 |  |  | 11 |  |  | 8 |
Total share-based compensation: |  |  |  |  |  |  |  |
Pre-tax compensation expense |  | 8 |  |  | 9 |  |  | 30 |  |  | 23 |
Income tax benefit |  | (1) |  |  | (1) |  |  | (2) |  |  | (2) |
Total share-based compensation expense, net of income taxes |  | $ | 7 |  |  | $ | 8 |  |  | $ | 28 |  |  | $ | 21 |
Schedule of valuation assumptions for stock options | We estimated the fair value of each option grant by using the Black-Scholes option-pricing model with the following assumptions:
|  | Nine Months Ended September 30,
|  | 2024 |  | 2023
Expected life (in years) |  | 5.5 |  | 5.5
Risk-free interest rate |  | 4.2% |  | 4.0%
Expected volatility |  | 28.1% |  | 28.3%
Expected dividend yield |  | 2.9% |  | 2.9%
Schedule of stock option transactions | Stock option activity for year-to-date 2024 is as follows:
|  | Number of Options (in thousands) |  | Weighted Average Exercise Price per Share |  | Average Remaining Contractual Term (in years) |  | Aggregate Intrinsic Value
Outstanding as of December 31, 2023 |  | 1,953 |  | $ | 96.61 |  |  | 5.0 |  | $ | 29 |
Granted |  | 178 |  | 108.38 |  |  |  |  |
Exercised |  | (390) |  | 85.17 |  |  |  |  |
Cancelled |  | (44) |  | 101.45 |  |  |  |  |
Outstanding as of September 30, 2024 |  | 1,697 |  | $ | 100.35 |  |  | 5.3 |  | $ | 63 |
Exercisable as of September 30, 2024 |  | 1,347 |  | $ | 100.13 |  |  | 4.5 |  | $ | 50 |
Schedule of additional information pertaining to stock option activity | Additional information pertaining to stock option activity is as follows:
|  | Three Months Ended September 30, | Nine Months Ended September 30,
|  | 2024 |  | 2023 | 2024 |  | 2023
Weighted average grant date fair value of stock options granted (per share) |  | $ | — |  |  | $ | — |  | $ | 26.33 |  |  | $ | 23.80 |
Total intrinsic value of stock options exercised |  | 3 |  |  | 1 |  | 13 |  |  | 11 |
Schedule of restricted unit activity | The following table summarizes RSU activity year-to-date in 2024:
|  | Number of Restricted Shares (in thousands) |  | Weighted Average Fair Value per Share
Non-vested as of December 31, 2023 |  | 552 |  | $ | 92.05 |
Granted |  | 210 |  | 108.81 |
Vested |  | (174) |  | 87.46 |
Cancelled |  | (45) |  | 95.74 |
Non-vested as of September 30, 2024 |  | 543 |  | $ | 99.43 |
Summary of net changes in accumulated other comprehensive loss | The following is a summary of accumulated other comprehensive loss for year-to-date 2024 and 2023:
|  | Cumulative Translation Adjustment |  | Hedging Activities |  | Pension and Other Post-employment Benefits |  | AOCL
Balance as of December 31, 2023 |  | $ | (961) |  |  | $ | (48) |  |  | $ | (47) |  |  | $ | (1,056) |
Other comprehensive income (loss) before reclassification adjustments |  | 32 |  |  | (62) |  |  | 1 |  |  | (29) |
Loss reclassified from AOCL |  | — |  |  | 92 |  |  | 1 |  |  | 93 |
Tax (provision) |  | — |  |  | (8) |  |  | — |  |  | (8) |
Net other comprehensive income |  | 32 |  |  | 22 |  |  | 2 |  |  | 56 |
Balance as of September 30, 2024 |  | $ | (929) |  |  | $ | (26) |  |  | $ | (45) |  |  | $ | (1,000) |
|  | Cumulative Translation Adjustment |  | Hedging Activities |  | Pension and Other Post-employment Benefits |  | AOCL
Balance as of December 31, 2022 |  | $ | (1,008) |  |  | $ | 6 |  |  | $ | (46) |  |  | $ | (1,048) |
Other comprehensive (loss) before reclassification adjustments |  | (30) |  |  | (123) |  |  | (2) |  |  | (155) |
Loss reclassified from AOCL |  | — |  |  | 36 |  |  | 1 |  |  | 37 |
Tax benefit |  | — |  |  | 21 |  |  | 1 |  |  | 22 |
Net other comprehensive (loss) |  | (30) |  |  | (66) |  |  | — |  |  | (96) |
Balance as of September 30, 2023 |  | $ | (1,038) |  |  | $ | (60) |  |  | $ | (46) |  |  | $ | (1,144) |
Schedule of Stockholders Equity | The following Condensed Consolidated Statements of Equity and Redeemable Equity present information about the dividends per share for common stock for the periods indicated:
|  | Total Equity |  | Share-based Payments Subject to Redemption |  | Redeemable Non- Controlling Interests
|  | Preferred Stock |  | Common Stock |  | Additional Paid-In Capital |  | Treasury Stock |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Non-Redeemable Non-Controlling Interests |  |
Balance as of December 31, 2023 |  | $ | — |  |  | $ | 1 |  |  | $ | 1,146 |  |  | $ | (1,207) |  |  | $ | (1,056) |  |  | $ | 4,654 |  |  | $ | 14 |  |  | $ | 55 |  |  | $ | 43 |
Net income attributable to Ingredion |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 216 |  |  | — |  |  | — |  |  | — |
Net income attributable to non-controlling interests |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 2 |  |  | — |  |  | — |
Dividends declared, common stock ($0.78/share) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (52) |  |  | — |  |  | — |  |  | — |
Repurchases of common stock, net |  | — |  |  | — |  |  | — |  |  | (1) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Share-based compensation, net of issuance |  | — |  |  | — |  |  | — |  |  | 29 |  |  | — |  |  | — |  |  | — |  |  | (12) |  |  | — |
Other comprehensive (loss) |  | — |  |  | — |  |  | — |  |  | — |  |  | (6) |  |  | — |  | — |  | — |  |  | — |  |  | (1) |
Balance as of March 31, 2024 |  | $ | — |  |  | $ | 1 |  |  | $ | 1,146 |  |  | $ | (1,179) |  |  | $ | (1,062) |  |  | $ | 4,818 |  |  | $ | 16 |  |  | $ | 43 |  |  | $ | 42 |
Net income attributable to Ingredion |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 148 |  |  | — |  |  | — |  | — |  | — |
Net income (loss) attributable to non-controlling interests |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 3 |  |  | — |  |  | (1) |
Dividends declared, common stock ($0.78/share) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (52) |  |  | — |  |  | — |  |  | — |
Dividends declared, non-controlling interests |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (2) |  |  | — |  |  | — |
Repurchases of common stock, net |  | — |  |  | — |  |  | — |  |  | (65) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Share-based compensation, net of issuance |  | — |  |  | — |  |  | 1 |  |  | 11 |  |  | — |  |  | — |  |  | — |  |  | 7 |  |  | — |
Fair market value adjustment to non-controlling interests |  | — |  |  | — |  |  | (6) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 6 |
Purchases of non-controlling interests |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (40) |
Other comprehensive (loss) |  | — |  |  | — |  |  | — |  |  | — |  |  | (56) |  |  | — |  |  | — |  |  | — |  |  | — |
Balance as of June 30, 2024 |  | $ | — |  |  | $ | 1 |  |  | $ | 1,141 |  |  | $ | (1,233) |  |  | $ | (1,118) |  |  | $ | 4,914 |  |  | $ | 17 |  |  | $ | 50 |  |  | $ | 7 |
Net income attributable to Ingredion |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 188 |  |  | — |  |  | — |  |  | — |
Net income (loss) attributable to non-controlling interests |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 2 |  |  | — |  |  | (1) |
Dividends declared, common stock ($0.80/share) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (53) |  |  | — |  |  | — |  |  | — |
Dividends declared, non-controlling interests |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1) |  |  | — |  |  | — |
Repurchases of common stock, net |  | — |  |  | — |  |  | — |  |  | (21) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Share-based compensation, net of issuance |  | — |  |  | — |  |  | 4 |  |  | 9 |  |  | — |  |  | — |  |  | — |  |  | 4 |  |  | — |
Other comprehensive income |  | — |  |  | — |  |  | — |  |  | — |  |  | 118 |  |  | — |  |  | 1 |  |  | — |  |  | 1 |
Balance as of September 30, 2024 |  | $ | — |  |  | $ | 1 |  |  | $ | 1,145 |  |  | $ | (1,245) |  |  | $ | (1,000) |  |  | $ | 5,049 |  |  | $ | 19 |  |  | $ | 54 |  |  | $ | 7 |
|  | Total Equity |  | Share-based Payments Subject to Redemption |  | Redeemable Non- Controlling Interests
|  | Preferred Stock |  | Common Stock |  | Additional Paid-In Capital |  | Treasury Stock |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Non-Redeemable Non-Controlling Interests |  |
Balance as of December 31, 2022 |  | $ | — |  |  | $ | 1 |  |  | $ | 1,132 |  |  | $ | (1,148) |  |  | $ | (1,048) |  |  | $ | 4,210 |  |  | $ | 16 |  |  | $ | 48 |  |  | $ | 51 |
Net income attributable to Ingredion |  | — |  | — |  | — |  |  | — |  |  | — |  |  | — |  |  | 191 |  |  | — |  |  | — |  |  | — |
Net income attributable to non-controlling interests |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 3 |  |  | — |  |  | — |
Dividends declared, common stock ($0.71/share) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (47) |  |  | — |  |  | — |  |  | — |
Share-based compensation, net of issuance |  | — |  |  | — |  |  | 1 |  |  | 21 |  |  | — |  |  | — |  |  | — |  |  | (10) |  |  | — |
Other comprehensive (loss) |  | — |  |  | — |  |  | — |  |  | — |  |  | (50) |  |  | — |  |  | (6) |  |  | — |  |  | — |
Balance as of March 31, 2023 |  | $ | — |  |  | $ | 1 |  |  | $ | 1,133 |  |  | $ | (1,127) |  |  | $ | (1,098) |  |  | $ | 4,354 |  |  | $ | 13 |  |  | $ | 38 |  |  | $ | 51 |
Net income attributable to Ingredion |  | — |  |  | — |  |  | — |  |  | — |  | — |  | — |  |  | 163 |  |  | — |  |  | — |  |  | — |
Net income attributable to non-controlling interests |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 1 |  |  | — |  |  | — |
Dividends declared, common stock ($0.71/share) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (48) |  |  | — |  |  | — |  |  | — |
Dividends declared, non-controlling interests |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1) |  |  | — |  |  | — |
Share-based compensation, net of issuance |  | — |  |  | — |  |  | 2 |  |  | 11 |  |  | — |  |  | — |  |  | — |  |  | 5 |  |  | — |
Fair market value adjustment to non-controlling interests |  | — |  |  | — |  |  | 7 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (7) |
Other comprehensive (loss) |  | — |  |  | — |  |  | — |  |  | — |  |  | (21) |  |  | — |  |  | (1) |  |  | — |  |  | (1) |
Balance as of June 30, 2023 |  | $ | — |  |  | $ | 1 |  |  | $ | 1,142 |  |  | $ | (1,116) |  |  | $ | (1,119) |  |  | $ | 4,469 |  |  | $ | 12 |  |  | $ | 43 |  |  | $ | 43 |
Net income attributable to Ingredion |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 158 |  |  | — |  |  | — |  |  | — |
Net income attributable to non-controlling interests |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 2 |  |  | — |  |  | — |
Dividends declared, common stock ($0.78/share) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (52) |  |  | — |  |  | — |  |  | — |
Dividends declared, non-controlling interests |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1) |  |  | — |  |  | — |
Repurchases of common stock |  | — |  |  | — |  |  | — |  |  | (101) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Share-based compensation, net of issuance |  | — |  |  | — |  |  | 1 |  |  | 6 |  |  | — |  |  | — |  |  | — |  |  | 6 |  |  | — |
Purchases of non-controlling interests |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (2) |
Other comprehensive (loss) |  | — |  |  | — |  |  | — |  |  | — |  |  | (25) |  |  | — |  |  | — |  |  | — |  |  | — |
Balance as of September 30, 2023 |  | $ | — |  |  | $ | 1 |  |  | $ | 1,143 |  |  | $ | (1,211) |  |  | $ | (1,144) |  |  | $ | 4,575 |  |  | $ | 13 |  |  | $ | 49 |  |  | $ | 41 |
Schedule of basic and diluted earnings per common share | The following tables present information about the computation of basic and diluted earnings per common share (“EPS”) for the periods presented:
|  | Three Months Ended September 30, 2024 |  | Three Months Ended September 30, 2023
|  | Net Income Attributable to Ingredion |  | Weighted Average Shares |  | Per Share Amount |  | Net Income Attributable to Ingredion |  | Weighted Average Shares |  | Per Share Amount
Basic EPS |  | $ | 188 |  |  | 65.3 |  | $ | 2.88 |  |  | $ | 158 |  |  | 66.0 |  | $ | 2.39 |
Effect of Dilutive Securities: |  |  |  |  |  |  |  |  |  |  |  |
Incremental shares from assumed exercise of dilutive stock options, vesting of dilutive RSUs and other awards |  |  |  | 1.2 |  |  |  |  |  | 1.0 |  |
Diluted EPS |  | $ | 188 |  |  | 66.5 |  | $ | 2.83 |  |  | $ | 158 |  |  | 67.0 |  | $ | 2.36 |
|  | Nine Months Ended September 30, 2024 |  | Nine Months Ended September 30, 2023
|  | Net Income Attributable to Ingredion |  | Weighted Average Shares |  | Per Share Amount |  | Net Income Attributable to Ingredion |  | Weighted Average Shares |  | Per Share Amount
Basic EPS |  | $ | 552 |  |  | 65.6 |  | $ | 8.41 |  |  | $ | 512 |  |  | 66.1 |  | $ | 7.75 |
Effect of Dilutive Securities: |  |  |  |  |  |  |  |  |  |  |  |
Incremental shares from assumed exercise of dilutive stock options, vesting of dilutive RSUs and other awards |  |  |  | 1.0 |  |  |  |  |  | 1.0 |  |
Diluted EPS |  | $ | 552 |  |  | 66.6 |  | $ | 8.29 |  |  | $ | 512 |  |  | 67.1 |  | $ | 7.63 |

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (d)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + References No definition available. + Details
Name: | us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration